GlaxoSmithKline and A*STAR’s Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
SINGAPORE, April 9, 2013 /PRNewswire/ –
State-of-the-art laboratory focused on developing new, improved formulations for added
GlaxoSmithKline (GSK) and A*STAR’s Institute of Chemical and Engineering Sciences
(ICES) have signed a five-year strategic agreement to develop new evidence based
formulations (EBFs) specifically for emerging markets. EBFs are medicines which are
reformulated to provide additional patient benefit.
ICES has a long standing relationship with GSK since 2003, and the development of EBFs
will further strengthen the relationship between both parties. The collaboration leverages
on ICES’ strengths and expertise in synthesis, formulation and process development, as
well as GSK’s vast experience in drug candidate selection, optimisation, and product
development in novel formulations. The collaboration will enhance ICES’ technical
expertise and know-how in drug product formulation, analytical techniques, development and
scale up. It will develop a pool of local expertise in specialised formulation for
pharmaceutical development in Singapore.
“Collaborating with GSK, a global leader in pharmaceuticals and healthcare provides an
opportunity for us to further our research and deepen our capabilities in formulation
science with skilled scientists and technical expertise. This venture will enable us to
develop future scientists and laboratory analysts with the right skills to grow this
industry in Singapore” said Dr Keith Carpenter, Executive Director, ICES.
The establishment of a joint partnership between ICES and GSK will position Singapore
as a regional centre for drug development for the emerging markets.
“This agreement with ICES is perfectly aligned with GSK’s strategic priority of
growing a diversified global business, whilst bringing affordable, quality GSK medicines
of value to more people who need them. Within GSK’s portfolio of off-patent products, EBFs
are an important part of our growth strategy, and our hope is that together with ICES we
will create a sustainable, scalable model to meet both specific market conditions and
patient requirements,” commented Duncan McKay, Vice President, Emerging Markets & Asia
Pacific R&D, GSK.
“We are pleased that GSK has chosen Singapore as a strategic partner to develop new
evidenced-based drug formulations. This is a strong endorsement of Singapore’s scientific
talent and capabilities. It also further reinforces Singapore’s offering as the base for
companies to generate insights and develop new solutions and market access strategies for
the fast growing emerging markets,” said Kevin Lai, Director, Biomedical Sciences,
Singapore Economic Development Board.
About Evidence Based Formulations (EBFs)
An Evidence-Based Formulation (EBF) is a differentiated drug that has been
reformulated to offer additional patient benefit. EBF’s are often fixed-dose combinations
of active drugs or new formulations with different pharmacokinetic properties, new routes
of delivery, or improved safety profiles. EBF’s are also referred to as Value Added
Formulations, or Incrementally Modified Drugs.
One of the world’s leading research-based pharmaceutical and healthcare companies is
committed to improving the quality of human life by enabling people to do more, feel
better and live longer. For further information please visit http://www.gsk.com.
About GSK in Singapore
Singapore is home to GSK’s Regional Headquarters (Emerging Markets & Asia Pacific), an
R&D facility (Biopolis), two global manufacturing and supply sites (Jurong & Quality
Road), a Stiefel manufacturing facility, and a state-of-the-art vaccines plant (Tuas).
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is the lead agency for
fostering world-class scientific research and talent for a vibrant knowledge-based and
innovation-driven Singapore. A*STAR oversees 14 biomedical sciences and physical sciences
and engineering research institutes, and six consortia & centres, located in Biopolis and
Fusionopolis as well as their immediate vicinity.
A*STAR supports Singapore’s key economic clusters by providing intellectual, human and
industrial capital to its partners in industry. It also supports extramural research in
the universities, and with other local and international partners.
For more information about A*STAR, please visit http://www.a-star.edu.sg.
About the Institute of Chemical and Engineering Sciences (ICES)
Institute of Chemical and Engineering Sciences (ICES) is a member of the Agency for
Science, Technology and Research (A*STAR). Established in 2002, its mission is to carry
out world class scientific research, to develop novel technology and to nurture creative
scientists and engineers to support economic growth in Singapore and to make a positive
difference to society. The research area covers chemistry and chemical engineering
science, combined with advanced analytical characterisation and measurement to develop
state of the art technology for the petrochemical, general chemical, fine chemical and
pharmaceutical industries. For more information, visit http://www.ices.a-star.edu.sg
 Growth in emerging markets especially China, Brazil, India and Russia will account
for nearly 40% of the global pharmaceutical market by 2016. – Roland Berger Strategy
Consultants, “Global Pharmaceutical Industry Is In A Strategic Crisis – Business Models
Must Be Adjusted”, January 2013
For media enquiries, please contact:
GSK contacts Garry Daniels (Singapore) Tel.: +65-6232-8187 Email: email@example.com
David Daley (London) Tel.: +44-(0)-20-8047-5502 Email: firstname.lastname@example.org
ICES contact Ms Caroline Chia Tel.: +65-6796-3884 Mobile: +65-9170-3988 Email: email@example.com
SOURCE Institute of Chemical and Engineering Sciences (ICES) & GSK